ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ — Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024. The AACR meeting will take place April 5-10, 2024, in San Diego, California.
Late-Breaking Research: Experimental and Molecular Therapeutics 1Topic: IBI3001: a potentially first-in-class site-specifically conjugated B7-H3/EGFR bispecific ADC for multiple solid tumorsAbstract Number: LB055Presentation Form: PosterPresentation Time：Sunday Apr 7, 2024 1:30 PM – 5:00 PMLocation: Poster Section 53Presenting Author: Dr. Kaijie He
Topic: IBI334, a novel ADCC-enhanced B7-H3/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumorsAbstract Number: LB056Presentation Form: PosterPresentation Time：Sunday Apr 7, 2024 1:30 PM – 5:00 PMLocation: Poster Section 53Presenting Author: Dr. Kaijie He
Topic: Discovery and preclinical characterization of IBI343, a site-specifically conjugated anti-Claudin18.2 ADC for treating solid tumorsAbstract Number: LB057Presentation Form: PosterPresentation Time：Sunday Apr 7, 2024 1:30 PM – 5:00 PMLocation: Poster Section 53Presenting Author: Dr. Kaijie He
Poster Session: Immunology – Single Target and Bispecific AntibodiesTopic: A novel TROP2-targeted immune stimulating antibody conjugate (ISAC) with potent anti-tumoral activity and acceptable safetyAbstract Number: 2718Presentation Form: PosterPresentation Time: Monday Apr 8, 2024 1:30 PM – 5:00 PMLocation: Poster Section 6Poster Board Number: 9Presenting Author: Dr. Huizhong Xiong
Poster Session: Immunology – Immune Modulation Employing Agonist or Co-Stimulatory ApproachesTopic: Tumor targeted-CD28 bispecific antibody with optimized potency, robust anti-tumoral activity and stringent CD3-dependenceAbstract Number: 5295Presentation Form: PosterPresentation Time: Tuesday Apr 9, 2024 1:30 PM – 5:00 PMLocation: Poster Section 3Poster Board Number: 4Presenting Author: Dr. Huizhong Xiong
Dr. Kaijie He, Vice President of Innovent, stated: "We aim to tackle drug resistance and enhance treatment outcomes in immunotherapy by developing next-generation bispecific antibodies, multi-specific antibodies and ADCs candidates. To select targets that can address broad-spectrum of tumor types is one of our main research direction. We are pleased to present preclinical data of innovative molecules at the AACR and accepted as Late-breaking Researches. We hope to benefit more patients with continuous advances in life science and technology. "
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable illnesses. Its pioneering therapies to treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 3 new drug applications under the NMPA review, 4 assets in Phase III or pivotal clinical trials and 20 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center.
Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Note:TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States.TYVYT® (sintilimab injection, Innovent)BYVASDA® (bevacizumab biosimilar injection, Innovent)HALPRYZA® (rituximab biosimilar injection, Innovent)SULINNO® (adalimumab biosimilar injection, Innovent)Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan.CYRAMZA® (ramucirumab, Eli Lilly). Cyramza® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.Retsevmo® (selpercatinib, Eli Lilly). Retsevmo® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.
Disclaimer: Innovent does not recommend any off-label usage.
Forward-looking statement
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.
The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
